GRAIL

Multi-Cancer Early Detection Company GRAIL Now Hiring For State-Of-The-Art Laboratory Facility in Research Triangle Park

February 25, 2021

- More than 100 Jobs Coming to Durham Campus this Year; Native North Carolinian Named Site Director —
- Virtual Open House Planned for April 27 -

DURHAM, N.C., February 25, 2021 – GRAIL, Inc., a healthcare company whose mission is to detect cancer early, is now hiring for its new state-of-the-art laboratory facility located in Research Triangle Park (RTP). The company expects to hire more than 100 employees for the site by the end of 2021.

GRAIL's RTP site, announced by North Carolina Gov. Roy Cooper last summer, is expected to open to employees in the spring and laboratory operations could begin as early as this fall. The 200,000-square-foot state-of-the-art facility in the Park Point Office and Life Science Park will feature office and warehouse space and a campus cafe and gym for employees, who could eventually number in the hundreds.

"Building our RTP team is an important step forward in making our novel multi-cancer early detection blood test widely available to patients and healthcare providers across the country," said Matthew Young, chief operating officer and chief financial officer at GRAIL. "We are already seeing the benefits of tapping into the large pool of skilled talent and innovative spirit the Triangle offers, and we look forward to growing our team with people who are excited and inspired by our mission to detect cancer early."

Andrew Crenshaw, a local North Carolinian with more than 20 years of experience in the clinical and biomedical research industry, recently joined GRAIL as vice president of operations and RTP site director.

Hiring is underway for laboratory scientists and technologists; equipment, quality, and automation engineers; and supply chain and warehouse personnel. Candidates are encouraged to visit grail.com/careers to view and apply for open positions. A virtual open house is planned for April 27 at noon ET to introduce GRAIL to the community and to view a video of the new facility. To register for the virtual event, please visit this link.

"As a native North Carolinian, it is an honor to be part of GRAIL's expansion to our great state," Crenshaw said. "For those passionate about joining a team pursuing a game-changing and potentially life-saving mission, we encourage you to apply for an open role."

GRAIL expects to introduce Galleri™ its multi-cancer early detection blood test, in the second quarter of this year.

About GRAIL

GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on saving lives and improving health by pioneering new technologies for early cancer detection. The company is using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to overcome one of medicine's greatest challenges with Galleri™, GRAIL's multicancer early detection test. An earlier version of Galleri demonstrated the ability to detect more than 50 types of cancers — over 45 of which lack recommended screening tests today — with a low false-positive rate of less than 1%. When cancer is detected, Galleri localizes the cancer signal with high accuracy, all from a single blood draw. GRAIL is headquartered in Menlo Park, California, with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies.

GRAIL Contacts

Corporate Communications Leigh Strope pr@grail.com

Investor Relations John Craighead ir@grail.com